Bactericidal activity of trovafloxacin (CP-99,219)

被引：16

作者：

Morrissey, I ^{[1
]}

机构：

[1] UNIV E LONDON,CHEMOTHERAPY RES UNIT,LONDON E15 4LZ,ENGLAND

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 1996年 / 38卷 / 06期

关键词：

D O I：

10.1093/jac/38.6.1061

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Trovafloxacin was found to be a typical quinolone producing a biphasic dose response against Escherichia coli, Staphylococcus aureus or Streptococcus pneumoniae. A reduced rate of kill was seen against Enterococcus faecalis, which is also typical of the quinolones. However, the bactericidal activity of trovafloxacin against S. aureus and S. pneumoniae was greater than most other quinolones previously tested. The enhanced bactericidal activity of trovafloxacin against S. aureus may be explained by the possession of a very strong bactericidal mechanism B. Trovafloxacin may prove to be a quinolone of choice against S. aureus infections.

引用

页码：1061 / 1066

页数：6

共 50 条

[1] Intracellular activity of trovafloxacin (CP-99,219) against Enterococcus faecium
HerreraInsua, I
JacquesPalaz, K
Murray, BE
Rakita, RM
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (04) : 552 - 553
[2] Analysis of the in vitro activity of trovafloxacin (CP-99,219) against Bacteroides species
Snydman, DR
McDermott, L
[J]. INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1996, 5 : S96 - S100
[3] Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219)
Wise, R
Mortiboy, D
Child, J
Andrews, JM
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (01) : 47 - 49
[4] Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys
Teng, RL
Girard, D
Gootz, TD
Foulds, G
Liston, TE
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) : 561 - 566
[5] In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens
Crokaert, F
Aoun, M
Duchateau, V
Grenier, P
Vandermies, A
Klastersky, J
[J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1996, 15 (08) : 696 - 698
[6] Dose-ranging study of CP-99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea
Hook, EW
Pinson, GB
Blalock, CJ
Johnson, RB
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (07) : 1720 - 1721
[7] Efficacy of trovafloxacin (CP-99,219), a new fluoroquinolone, in an animal model of intraabdominal sepsis
Onderdonk, AB
[J]. INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1996, 5 : S117 - S119
[8] IN-VITRO ACTIVITY OF THE NEW FLUOROQUINOLONE CP-99,219
NEU, HC
CHIN, NX
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (11) : 2615 - 2622
[9] Activity of the antibiotic CP-99,219 (trovafloxacin) in a mixed microflora growth system model of intraabdominal infections in humans
Ross, RA
Onderdonk, AB
[J]. INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1996, 5 : S110 - S112
[10] Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against Gram-positive cocci
Coque, TM
Singh, KV
Murray, BE
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 (05) : 1011 - 1016

← 1 2 3 4 5 →